J Korean Ophthalmol Soc.  2015 Jul;56(7):985-991. 10.3341/jkos.2015.56.7.985.

The Incidence of Increased Intraocular Pressure when Using 0.1% Fluorometholone after Photorefractive Keratectomy

• Kim WK
• Cho EY
• Kim HS
• Kim JK

• KMID: 2148796
• DOI: http://doi.org/10.3341/jkos.2015.56.7.985

Abstract

PURPOSE
To analyze the time and incidence of increased intraocular pressure (IOP) induced by 0.1% fluorometholone used to prevent corneal haze after photorefractive keratectomy (PRK).
METHODS
The present study included 826 patients (826 eyes) who underwent PRK between November 2012 and October 2013 and were followed up for more than 6 months. After surgery the patients were treated with 0.1% fluorometholone for 3-6 months according to their corneal conditions. The time and incidence was analyzed with the time and incidence when anti-glaucoma eye drops were used.
RESULTS
Anti-glaucoma eye drops were used in 312 eyes (38%). The anti-glaucoma eye drops were started before 4 weeks postoperatively in 105 eyes (13%) and postoperatively at 5-8 weeks in 86 eyes (10%), at 9-12 weeks in 83 eyes (10%), at 13-16 weeks in 25 eyes (3%) and after 17 weeks in 13 eyes (2%).
CONCLUSIONS
The overall incidence of increased IOP when treated with 0.1% fluorometholone for 3-6 months after PRK was approximately 38%. The incidence of increased IOP in each month for the first 3 months was almost identical implying that the longer 0.1 fluorometholone was used, the higher incidence of increased IOP occurred. These results can be helpful in educating patients regarding the risk of increased IOP and determining the follow-up period after PRK.

Keyword

Fluorometholone; Intraocular pressure; LASEK; Photorefractive keratectomy; Steroid-induced glaucoma

MeSH Terms

Fluorometholone*
Follow-Up Studies
Humans
Incidence*
Intraocular Pressure*
Keratectomy, Subepithelial, Laser-Assisted
Ophthalmic Solutions
Photorefractive Keratectomy*
Fluorometholone
Ophthalmic Solutions

Figure

• 

  Figure 1. The graph shows the time when the patients started to use anti glaucoma medication during 0.1% fluorometholone treatment after photorefractive keratectomy.

Reference

References

1. O'Brart DP, Shalchi Z, McDonald RJ. . Twenty-year follow-up of a randomized prospective clinical trial of excimer laser photo-refractive keratectomy. Am J Ophthalmol. 2014; 158:651–63.

2. Yuksel N, Bilgihan K, Hondur AM. . Long term results of Epi-LASIK and LASEK for myopia. Cont Lens Anterior Eye. 2014; 37:132–5.

3. Sia RK, Ryan DS, Edwards JD. . The US. army surface abla-tion study: comparison of PRK, MMC-PRK, and LASEK in mod-erate to high myopia. J Refract Surg. 2014; 30:256–64.

4. Hofmeister EM, Bishop FM, Kaupp SE, Schallhorn SC. Randomized dose-response analysis of mitomycin-C to prevent haze after photorefractive keratectomy for high myopia. J Cataract Refract Surg. 2013; 39:1358–65.

5. Corbett MC, O'Brart DP, Warburton FG, Marshall J. Biologic and environmental risk factors for regression after photorefractive keratectomy. Ophthalmology. 1996; 103:1381–91.

6. Baek SH, Choi SY, Chang JH. . Short-term effects of flurbipro-fen and diclofenac on refractive outcome and corneal haze after photorefractive keratectomy. J Cataract Refract Surg. 1997; 23:1317–23.

7. Kim SI, Oh TH. Effects of topical tranilast on corneal haze with the Pentacam(R) after photorefractive keratectomy. J Korean Ophthalmol Soc. 2014; 55:1277–83.

8. Deng Y, Wnag L, Liu C, Cai R. Effects of Dexamethasone, Fluorometholone and Florex on intraocular pressure after photo-refractive keratectomy. Hua Xi Yi Ke Da Xue Xue Bao. 1999; 30:205–7.

9. Vetrugno M, Quaranta GM, Maino A, Cardia L. A, comparative study of fluorometholone 0.2% and fluorometholone 0.1% acetate after photorefractive keratectomy. Eur J Ophthalmol. 2000; 10:39–45.

10. Machat JJ. Double-blind corticosteroid trial in identical twins fol-lowing photorefractive keratectomy. Refract Corneal Surg. 1993; 9((2 Suppl)):S105–7.

11. Levy Y, Hefetz L, Zadok D. . Refractory intraocular pressure increase after photorefractive keratectomy. J Cataract Refract Surg. 1997; 23:593–4.

12. Yamaguchi T, Murat D, Kimura I. . Diagnosis of steroid-in-duced glaucoma after photorefractive keratectomy. J Refract Surg. 2008; 24:413–5.

13. Morales J, Good D. Permanent glaucomatous visual loss after pho-torefractive keratectomy. J Cataract Refract Surg. 1998; 24:715–8.

14. Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012; 47:66–80.

15. Morrison E, Archer DB. Effect of fluorometholone (FML) on the intraocular pressure of corticosteroid responders. Br J Ophthalmol. 1984; 68:581–4.

16. Javadi MA, Mirbabaei-Ghafghazi F, Mirzade M. . Steroid in duced ocular hypertension following myopic photorefractive keratectomy. J Ophthalmic Vis Res. 2008; 3:42–6.

17. Lee KM, Kim MK, Wee WR, Lee JH. Risk factors of the steroid in-duced ocular hypertension after corneal refractive surgery. J Korean Ophthalmol Soc. 2010; 51:1333–7.

18. Hashemi H, Miraftab M, Asgari S. Comparison of the visual out-comes between PRK-MMC and phakic IOL implantation in high myopic patients. Eye (Lond). 2014; 28:1113–8.

19. Kang H, Choe CM, Choi TH, Kim SK. Comparison of clinical re-sults between transepithelial photorefractive keratectomy and brush photorefractive keratectomy. J Korean Ophthalmol Soc. 2014; 55:1284–90.

20. Kuo IC, Lee SM, Hwang DG. Late-onset corneal haze and myopic regression after photorefractive keratectomy (PRK). Cornea. 2004; 23:350–5.

21. Kim WK, Cho EY, Kim HS. . Analysis of postoperative intra-ocular pressure underestimation measured with non contact ton-ometry after corneal refractive surgery. J Korean Ophthalmol Soc. 2014; 55:167–72.

22. Nagy ZZ, Szabó A, Krueger RR, Süveges I. Treatment of intra-ocular pressure elevation after photorefractive keratectomy. J Cataract Refract Surg. 2001; 27:1018–24.

23. Park HS, Choi CY, Bae JH, Kim JM. The effect of fixed combina-tion of brinzolamide 1% and timolol 0.5% in normal-tension glaucoma. J Korean Ophthalmol Soc. 2014; 55:1056–63.

24. Jang SR, Lee MV, Ahn JH. Comparison of dorzolamide-timolol fixed combination and latanoprost, effects on intraocular pressure and ocular pulse amplitude. J Korean Ophthalmol Soc. 2014; 55:854–9.

25. Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of com-mon topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013; 2:55–72.